Tier 4 — mechanistic

Cerebral edema associated with betaine treatment in classical homocystinuria

A M Devlin, L Hajipour, A Gholkar, H Fernandes, V Ramesh, A A M Morris
The Journal of pediatrics 2004 144(4):545-548

Bibliography

PubMed
PMID 15069409
DOI
10.1016/j.jpeds.2003.12.041
Funding
Funding was not specified in the indexed record or accessible funding metadata.
Competing interests
A competing-interest declaration was not available in the indexed record or accessible disclosure metadata.

Study snapshot

DesignCase report
ModelHuman participants
SampleOne child with classical homocystinuria
InterventionBetaine treatment
DurationEdema 4-6 weeks after treatment began
EndpointsCerebral edema; Adverse-event management

What the study showed, in plain terms

Published in 2004, this source examined prescription betaine and inherited metabolic disorders. Design: Case report. Sample/model: One child with classical homocystinuria. The exposure or intervention was Betaine treatment. Follow-up or treatment period: Edema 4-6 weeks after treatment began.

The child developed cerebral edema and recovered after emergency treatment and withdrawal of betaine.

Single rare-disease case; causal mechanism and incidence cannot be established from this report alone.

Continue with TMG Data Center

Continue with TMG, Methylation and MTHFR: Understanding the Evidence

Key findings

  • The child developed cerebral edema and recovered after emergency treatment and withdrawal of betaine.
  • The recorded outcome domains were Cerebral edema; Adverse-event management.

What this study can and cannot tell us

  • Single rare-disease case; causal mechanism and incidence cannot be established from this report alone.
  • A case report or series cannot estimate how often an event occurs or establish causality without alternative explanations and a suitable comparator.
  • Source basis: Indexed abstract and bibliographic data. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
First Revision of the Guidelines for the Diagnosis and Management of Remethylation Disorders
Giorgia Olivieri et al. · Journal of inherited metabolic disease · 2026
Tier 2
Guidelines for the diagnosis and management of cystathionine beta-synthase deficiency
Andrew A M Morris et al. · Journal of inherited metabolic disease · 2017
Tier 4
Postauthorization safety study of betaine anhydrous
Ulrike Mütze et al. · Journal of inherited metabolic disease · 2022
Tier 4
Cystathionine beta synthase deficiency and brain edema associated with methionine excess under betaine supplementation: Four new cases and a review of the evidence
Bernd C Schwahn et al. · JIMD reports · 2020
Tier 2
Efficacy and pharmacokinetics of betaine in CBS and cblC deficiencies: a cross-over randomized controlled trial
Apolline Imbard et al. · Orphanet journal of rare diseases · 2022

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology